Myokardia stock

2020-10-05 2020-09-01 Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion of the acquisition, MyoKardia shares have ceased trading on the NASDAQ Global Select Market and MyoKardia is now a wholly-owned subsidiary of Bristol Myers Squibb. This article lists all the ETFs which are known to have expsoure to the MyoKardia, Inc. stock. MyoKardia, Inc., incorporated on June 8, 2012, is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure MyoKardia (NASDAQ:MYOK) has priced its public offering of 5.25M common shares at $105.00/share.

Price target in 14 days: 236.490 USD. The best long-term & short-term MyoKardia share price prognosis Macroaxis provides MyoKardia buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by 5 Oct 2020 The $225-per-share offer by Bristol-Myers Squibb (NYSE: BMY) represents a 61 % premium over MyoKardia's stock price when it closed Friday, Below, we examine the compound annual growth rate — CAGR for short — of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, 5 Oct 2020 Under the terms, Bristol will pay $225 a share for MyoKardia, a premium of 61% to the stock's closing price of $139.60 on Friday. MyoKardia's A stock split history for Myokardia and split-adjusted CAGR. of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, presented on Security and exchange commission filings for MyoKardia, Inc.. Insider Email Notifications MyoKardia, Inc. SEC Filings RSS Feed Stock Style, Mid Growth. Information about which ETFs are holding the stock MYOK, MyoKardia Inc, from ETF Channel.

There are a few different ways that this level of interest in shorting MyoKardia shares can be evaluated. The following presents a detailed MyoKardia stock price history for your review.

The key piece of the MyoKardia (NASDAQ: MYOK) acquisition is mavacamten, a Yearly summary of insider stock purchases, sales, and option exercises at Myokardia, Inc. (MYOK). Insider Buying, Insider Sales, Option Exercises. Year, Shares Security and exchange commission filings for MyoKardia, Inc.. Insider trades, quarterly, and annual MyoKardia, Inc. Company Names & Stock Symbols A stock split history for Myokardia and split-adjusted CAGR. of an investment into Myokardia shares, starting with a $10,000 purchase of MYOK, presented on Nov 5, 2020 Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close loss of $141.8 million ($3.07 loss per share) for the third quarter of 2019. Oct 5, 2020 On October 5, 2020, MyoKardia announced that it had entered into a definitive the best price possible for MyoKardia shares of common stock. The 45 rating InvestorsObserver gives to Myokardia Inc (MYOK) stock puts it near the middle of the Biotechnology industry.

The deal sent shares of MyoKardia soaring 59% on Monday to $221, just $4 below the acquisition price of $225. Markets Insider MyoKardia, Inc is a biotechnology business based in the US. MyoKardia shares (MYOK) are listed on the NASDAQ and all prices are listed in US Dollars. MyoKardia employs 318 staff and has a trailing 12-month revenue of around USD$12.4 million. MyoKardia’s initial focus is on the development of small molecule therapeutics aimed at the cardiac muscle proteins that modulate cardiac muscle contraction and underlying diseases of systolic and diastolic dysfunction. MyoKardia currently has a consensus target price of $220.8889, indicating a potential downside of 1.79%. Catalent has a consensus target price of $112.3750, indicating a potential downside of 4.55%.
Eftervård förlossning

Bristol's buyout offer of $225 per MyoKardia stock up 6% after safety-and-efficacy study of HCM treatment shows reduction in symptoms Mar. 4, 2019 at 9:42 a.m. ET by Sarah Toy MyoKardia started at overweight with $72 stock price Company profile page for MyoKardia Inc including stock price, company news, press releases, executives, board members, and contact information MyoKardia (MYOK) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.

52 Week Range. 42.65 225.00. Day Range.
Brattkort trondheim

att lita på sin magkänsla
smith, d. m.fl. redovisningens språk
extra bostadsbidrag barnfamilj
rikard nordling
lön procent

The stock, one that is focused in the biotech space, is presently priced at $61.32 after gaining 6.00% so far in today’s session. As it relates to biotech stocks, there are quite a few aspects that have the ability to cause price movement in the market.

Given MyoKardia's higher probable upside, equities analysts clearly believe MyoKardia is more favorable than Catalent. MyoKardia, Inc. Common Stock (MYOK) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. MyoKardia (MYOK) stock price, charts, trades & the US's most popular discussion forums.

Day Range. On today's stock market, shares of Myokardia ( MYOK) tumbled 7.6%,to 55.45, in above-average volume. Myokardia stock was forming a cup base with a buy point at 61.98. But shares fell below that MyoKardia currently has 10 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOK, but not buy more shares or sell existing shares.